Shunbin Xiong, Ph.D.
Department of Genetics, Division of Discovery Science
About Dr. Shunbin Xiong
Shunbin Xiong was born in southeast region of China, and received his bachelor degree in Biochemistry at Fudan University in Shanghai. He completed his Ph.D. at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. After he finished his postdoctoral training in Baylor College of Medicine, he moved to The University of Texas, M.D. Anderson Cancer Center in 1999. He is currently an Assistant Professor in the Department of Genetics. Dr. Xiong’s research focus is to investigate p53 pathway using genetically modified mouse models. Tumor suppressor gene p53 is often mutated or inhibited by its negative regulators, Mdm2 and Mdm4, in human cancers. Dr. Xiong has discovered Mdm2 and Mdm4 cooperatively inhibit p53 activity during the development of the central nervous system, and Mdm2 and Mdm4 suppress p53 activity in embryonic development and adult stage, respectively. Furthermore, he shows overexpression of Mdm4 induces tumorigenesis and has a p53-independent function in mice. Dr. Xiong also demonstrates that Mdm4 overexpression cooperates with an oncogenic K-ras mutation to drive lung tumorigenesis in vivo. Dr. Xiong is also working on mutant p53 gain of function (GOF) in tumorigenesis and cancer metastasis. His work indicates phospholipase Pla2g16 mediates mutant p53 GOF in osteosarcoma metastasis. Dr. Xiong has also discovered different p53 mutations driving mammary tumorigenesis with distinct GOF ability. His research goal is to understand p53 pathway in vivo and identify therapeutic targets in cancer treatment.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1995 | Shanghai Institute of Biochemistry, Chinese Academy Of Sciences, Shanghai, CHN, PHD, Biochemistry |
| 1990 | Fudan University, Shanghai, CHN, BS, Biochemistry |
Selected Publications
Peer-Reviewed Articles
- Xiong S, Chachad D, Zhang Y, Gencel-Augusto J, Sirito M, Pant V, Yang P, Sun C, Chau G, Qi Y, Su X, Whitley EM, El-Naggar AK, Lozano G. Differential gain-of-function activity of three p53 hotspot mutants in vivo. Cancer Res 82(10):1926-1936, 2022. e-Pub 2022. PMID: 35320355.
- Pant V, Aryal NK, Xiong S, Chau GP, Fowlkes NW, Lozano G. Alterations of the MDM2 C-terminus differentially impact its function in vivo. Cancer Res 82(7):1313-1320, 2022. e-Pub 2022. PMID: 35078816.
- Kim MP, Li X, Deng J, Zhang Y, Dai B, Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, McDaniel JM, Xiong S, Koay EJ, McAllister F, Bristow CA, Heffernan TP, Maitra A, Liu B, Barton MC, Wasylishen AR, Fleming JB, Lozano G. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov 11(8):2094-2111, 2021. e-Pub 2021. PMID: 33839689.
- Zhou X, Beilter A, Xu Z, Gao R, Xiong S, Paulucci-Holthauzen A, Lozano G, de Crombrugghe B, Gorlick R. Wnt/ß-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. Cell Death Dis 12(6):521, 2021. e-Pub 2021. PMID: 34021120.
- Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Xiong S, Lozano G, Pellagatti A, Boultwood J, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell 39(4):529-547.e7, 2021. e-Pub 2021. PMID: 33667384.
- Xiong Y, Zhang Y, Xiong S, Williams-Villalobo AE. A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer. Biology (Basel) 9(9), 2020. e-Pub 2020. PMID: 32932978.
- Pant V, Xiong S, Wasylishen AR, Larsson CA, Aryal NK, Chau G, Tailor RC, Lozano G. Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity. Proc Natl Acad Sci U S A 116(35):17429-17437, 2019. e-Pub 2019. PMID: 31409715.
- Zhang Y, Xiong S, Liu B, Pant V, Celii F, Chau G, Elizondo-Fraire AC, Yang P, You MJ, El-Naggar AK, Navin NE, Lozano G. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases. Nat Commun 9(1):3953, 2018. e-Pub 2018. PMID: 30262850.
- Ortiz GJ, Li Y, Post SM, Pant V, Xiong S, Larsson CA, El-Naggar AK, Johnson DG, Lozano G. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene 37(3):332-340, 2018. e-Pub 2017. PMID: 28925402.
- Pourebrahim R, Zhang Y, Liu B, Gao R, Xiong S, Lin PP, McArthur MJ, Ostrowski MC, Lozano G. Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. Genes Dev 31(18):1847-1857, 2017. e-Pub 2017. PMID: 29021240.
- Pant V, Larsson CA, Aryal N, Xiong S, You MJ, Quintas-Cardama A, Lozano G. Tumorigenesis promotes Mdm4-S overexpression. Oncotarget 8(16):25837-25847, 2017. PMID: 28460439.
- Xiong S, Pant V, Zhang Y, Aryal NK, You MJ, Kusewitt D, Lozano G. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. J Pathol 241(4):501-510, 2017. e-Pub 2017. PMID: 27925213.
- Zhang Y, Xiong S, Li Q, Hu S, Tashakori M, Van Pelt C, You MJ, Pageon L, Lozano G. Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol 233(4):380-91, 2014. e-Pub 2014. PMID: 24789767.
- Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, Rotter V, Liu B, El-Naggar AK, Donehower LA, Martinez LA, Lozano G. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A 111(30):11145-50, 2014. e-Pub 2014. PMID: 25024203.
- Xiong S, Mu T, Wang G, Jiang X. Mitochondria-mediated apoptosis in mammals. Protein Cell 5(10):737-49. e-Pub 2014. PMID: 25073422.
- Li Q, Zhang Y, El-Naggar AK, Xiong S, Yang P, Jackson JG, Chau G, Lozano G. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res 12(6):901-11, 2014. e-Pub 2014. PMID: 24598047.
- Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 27(17):1857-67, 2013. e-Pub 2013. PMID: 23973961.
- McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, Krafcik F, Rodriguez-Galindo C, Wilson M, Xiong S, Lozano G, Sage J, Fu L, Louhibi L, Trimarchi J, Pani A, Smeyne R, Johnson D, Dyer MA. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 20(2):260-275, 2011. PMID: 21840489.
- Pant V, Xiong S, Iwakuma T, Quintás-Cardama A, Lozano G. Mdm2-Mdm4 heterodimerization is critical for. Proc Natl Acad Sci U S A 108(29):11995-2000, 2011. e-Pub 2011. PMID: 21730132.
- Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK, Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 121(3):893-904, 2011. PMID: 21285512.
- Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, Valentin-Vega YA, Post SM, Lozano G. Spontaneous Tumorigenesis in Mice Overexpressing the p53-Negative Regulator Mdm4. Cancer Res 70(18):7148-54, 2010. e-Pub 2010. PMID: 20736370.
- Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM, Lozano G. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 68(21):8968-75, 2008. PMID: 18974141.
- Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, Box NF, Lozano G. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol 213(4):360-8, 2007. PMID: 17893884.
- Xiong S, Van Pelt CS, Elizondo-Fraire AC, Fernandez-Garcia B, Lozano G. Loss of Mdm4 Results in p53-Dependent Dilated Cardiomyopathy. Circulation 115(23):2925-2930, 2007. e-Pub 2007. PMID: 17533180.
- Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A 103(9):3226-31, 2006. e-Pub 2006. PMID: 16492743.
- Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. Tissue specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 26(1):192-198, 2006. PMID: 16354690.
- Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20(56):8066-74, 2001. PMID: 11781819.
- Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 61(4):1727-32, 2001. PMID: 11245489.
- Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60(13):3655-61, 2000. PMID: 10910082.
- Xiong S, Chirala SS, Wakil SJ. Sterol regulation of human fatty acid synthase promoter I requires nuclear factor-Y and Sp-1 binding sites. Proc Natl Acad Sci U S A 97(8):3948-3953, 2000. PMID: 10759542.
- Xiong S, Chirala SS, Hsu MH, Wakil SJ. Identification of thyroid hormone response elements in the human fatty acid synthase promoter. Proc Natl Acad Sci U S A 95(21):12260-5, 1998. PMID: 9770474.
Invited Articles
- Xiong S. Mouse models of Mdm2 and Mdm4 and their clinical implications. Chin J Cancer 32(7):371-5, 2013. e-Pub 2013. PMID: 23327795.
- Xiong S, Parker-Thornburg J, Lozano G. Developing genetically engineered mouse models to study tumor suppression. Curr Protoc Mouse Biol 2(1):9-24, 2012. PMID: 22582146.
Patient Reviews
CV information above last modified April 08, 2024